Innovent Biologics Inc (IVBXF PINK) stock market data APIs
$10.3269
0(0%)
as of November 3, 2026
Try our APIs with
free plan!
Innovent Biologics Inc Financial Data Overview
Price chart is built with
Anychart
Innovent Biologics, Inc., a biopharmaceutical company, engages in the research and development of antibody and protein medicine products in the People's Republic of China, the United States, Europe, and internationally. The company discovers, develops, manufactures, and commercializes monoclonal antibodies and other drugs for the treatment of oncology, ophthalmology, autoimmune, cardiovascular, and metabolic diseases. Its commercial stage product portfolio includes TYVYT (sintilimab injection), BYVASDA (bevacizumab injection), SULINNO (adalimumab injection), HALPRYZA (rituximab injection), PEMAZYRE (pemigatinib), olverembatinib, Cyramza (ramucirumab), Retsevmo (selpercatinib), FUCASO (Equecabtagene Autoleucel), SINTBILO (tafolecimab injection), DUPERT (fulzerasib), DOVBLERON (taletrectinib adipate), Jaypirca (pirtobrutinib), limertinib, SYCUME (teprotumumab N01 injection), mazdutide, PECONDLE (picankibart injection), and TABOSUN(Ipilimumab N01 injection). In addition, it sells and distributes pharmaceutical products; and offers consultation and research and development services. The company was incorporated in 2011 and is headquartered in Suzhou, the People's Republic of China.
Prev. Close
10.3269
Open
10.3269
High
10.3269
Low
10.3269
52 wk Range
9.1-15.008
Market Cap
17 561 M
P/E Ratio
111.8889
Shares Outstanding
1 744 M
Revenue
15 706 M
EPS
-0.0628
Beta
0.357
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Innovent Biologics Inc data using free add-ons & libraries
Get Innovent Biologics Inc Fundamental Data
Innovent Biologics Inc Fundamental data includes:
- Net Revenue: 15 706 M
- EBITDA: 1 803 M
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2021-06-30
- EPS/Forecast: 0
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Innovent Biologics Inc News
New
Pfizer Raises Full-Year Outlook Following Third-Quarter Beat
Pfizer (PFE) raised its full-year outlook on Tuesday as the drugmaker reported third-quarter results Keep reading this article with Yahoo Finance Plus Silver Upgrade to Silver Silver Premium news ...
Altruist Biologics' Integrated CMC Platform Supports NMPA Acceptance of NDA for Localized Manufacturing of Multinational Client's Biologic
HANGZHOU, China, Oct. 29, 2026 /PRNewswire/ -- Altruist Biologics, a world-class contract development and manufacturing organization (CDMO) and wholly owned subsidiary of Innovent Biologics (1801.HK),...
Innovent Announces NMPA Acceptance of a New Indication Application of Sintilimab for the Treatment of Advanced Melanoma
SAN FRANCISCO and SUZHOU, China, Oct. 26, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializ...
Innovent reports cancer drug results in breast, lung, pancreatic tumors
[A cancer patient sits in a wheelchair with an IV drip looking stressed and sad. Asian Woman receiving IV therapy in a wheelchair showing visible signs of stress and depression] chanakon laorob/iStock...
Get Innovent Biologics Inc fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.